Nigeria Pharmaceuticals and Healthcare Report Q1 2010

Executive Summary ......................5
SWOT Analysis..............................6
Nigeria Pharmaceuticals And Healthcare Industry SWOT................. 6
Nigeria Political SWOT................................ 7
Nigeria Economic SWOT.............................. 7
Nigeria Business Environment SWOT........... 8
Pharmaceutical Business Environment Ratings ..............9
Table: Middle East And Africa (MEA) – Regional Pharmaceutical Business Environment Ratings for Q110 ................ 9
Limits To Potential Returns ........................ 10
Risks To Realisation Of Returns ................. 10
Nigeria – Market Summary ..........12
Regulatory Regime......................13
Recent Regulatory Developments ............... 14
Intellectual Property Regime ...................... 16
Counterfeit Drugs ....................................... 16
Recent Developments in Regards to Counterfeit Drugs .................... 18
Table: Implementation Key To Success Now .................................... 19
Pricing And Reimbursement Regime........... 20
Industry Developments...............22
Epidemiology........ 22
Maternal and Child Health......................... 23
Communicable Diseases ............................. 24
HIV/AIDS.............. 25
Recent Infectious Diseases Developments......................................... 27
Healthcare Sector ....................................... 27
Healthcare Financing................................. 28
Healthcare Provision.................................. 29
Recent Healthcare Sector Developments .... 30
Healthcare Reforms .................................... 31
Health Insurance ........................................ 32
Traditional African Medicine...................... 34
National Drug Policy.................................. 35
Medical Devices.......................................... 37
Recent Developments In The Medical Devices Market ..................... 38
Table: Nigeria Free Zones: Key Incentives....................................... 38
Industry Forecast Scenario .........40
Overall Market Forecasts ........................... 40
Key Growth Factors – Industry................... 41
Key Growth Factors – Macroeconomic ...... 43
Table: Nigeria - Economic Activity, 2006 – 2014 ............................. 46
Prescription Drug Market Forecast............ 47
Patented Drug Market Forecast ................. 48
Generic Drug Market Forecast................... 49
OTC Drug Market Forecast........................ 50
Pharmaceutical Trade Forecasts................ 52
Other Healthcare Data Forecasts............... 54
Key Risks To BMI’s Forecasts .................... 55
Competitive Landscape..............56
Domestic Pharmaceutical Sector................ 57
Recent Domestic Company Developments ........................................ 59
Foreign Pharmaceutical Sector .................. 60
Recent Foreign Company Developments .... 61
Research and Development......................... 62
Company Monitor........................63
Multinational Company Profiles...................... 63
Pfizer .................... 63
Novartis ................ 66
Sanofi-Aventis....... 67
GlaxoSmithKline (GSK).............................. 68
Merck & Co .......... 69
Indigenous Producers ...................................... 70
Nigeria-German Chemicals PLC (NGC) .... 70
Emzor.................... 72
Fidson Healthcare ...................................... 74
Archy .................... 76
Neros Pharmaceuticals............................... 77
Drugfield Pharmaceuticals Limited............ 78
Neimeth................. 79
Country Snapshot: Nigeria Demographic Data...............80
Section 1: Population.................................. 80
Table: Demographic Indicators, 2005-2030..................................... 80
Table: Rural/Urban Breakdown, 2005-2030 .................................... 81
Section 2: Education And Healthcare......... 81
Table: Education, 2002-2005 ..................... 81
Table: Vital Statistics, 2005-2030............... 81
Section 3: Labour Market And Spending Power ............................... 82
Table: Consumer Expenditure, 2000-2012 (US$) ............................. 82
BMI Methodology ........................83
How We Generate Our Pharmaceutical Industry Forecasts .................. 83
Pharmaceutical Business Environment Ratings Methodology ............... 84
Ratings Overview........................................ 84
Table: Pharmaceutical Business Environment Indicators ................ 85
Weighting.............. 85
Table: Weighting Of Components............... 86
Sources ...................... 86
Forecast Tables ...........................87